logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health gets licence to manufacture weight management product Slimbiome in India

Stephen O'Hara, OptiBiotix’s CEO commented: "Achieving FSSAI approval so quickly is a significant achievement and is an important step in completing the supply chain"

Slim woman
OptiBiotix revealed at the start of January this year that it had inked an agreement with Zeon in return for a 50% share of the profits

OptiBiotix Health PLC (LON:OPTI) said it has received a licence from the Food Standards and Safety Authority India (FSSAI) for its award-winning weight management product, SlimBiome to be manufactured in India.

The AIM-listed life sciences firm said approval was gained by OptiBiotix's manufacturing partner, Zeon Life Sciences, for both SlimBiome and SlimBiome containing products.

READ: OptiBiotix jumps as it inks supply and profit sharing agreement for SlimBiome in India

It pointed out that FSSAI licence approval involves both ingredient and quality verification to ensure the product and manufacturing process is of a high standard and is an essential regulatory requirement to manufacture and distribute food products in India.

The licence approval allows Zeon to fulfil orders arising from OptiBiotix's recent visit to India for SlimBiome and SlimBiome containing products in its own manufacturing site. 

The group said: ”This is a strategic step by OptiBiotix to add manufacturing in Asia to the supply chain and extend the market opportunity for its patented award-winning weight management product into the fast-growing Indian market with an established partner.”

It noted that Zeon includes major Indian and international healthcare companies such as Danone, GNC, Decathlon, Sun Pharma and Herbalife amongst its customers and was awarded Nutraceutical Manufacturing Company of the Year in 2017 by The Associated Chambers of Commerce and Industry of India.

Stephen O'Hara, OptiBiotix’s CEO commented: "Achieving FSSAI approval so quickly is a significant achievement and is an important step in completing the supply chain to meet the needs of existing and new corporate partners in India and Southern Asia.

“This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, and white label and own label branded consumer and pharmaceutical products across multiple channels with industry partners from around the world."

OptiBiotix revealed at the start of January this year that it had inked an agreement with Zeon, granting the firm an exclusive licence to manufacture and supply SlimBiome in India in return for a 50% share of the profits.

Quick facts: OptiBiotix Health PLC

Price: 64 GBX

AIM:OPTI
Market: AIM
Market Cap: £54.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: European healthcare broker sets 97p price target for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive London following a research note whcih has been published on the company by Goetz partners - which has set OPTI a price target of 97p. O'Hara says Goetz partners are a leading European Investment Bank and broking firm and...

on 11/9/19

2 min read